A Phase II, Two-arm Study to Investigate Tepotinib Combined With Osimertinib in MET Amplified, Advanced or Metastatic NSCLC Harboring Activating EGFR Mutations and Having Acquired Resistance to Prior Osimertinib Therapy (INSIGHT 2)
A Phase II, Two-arm Study to Investigate Tepotinib Combined With Osimertinib in MET Amplified, Advanced or Metastatic NSCLC Harboring Activating EGFR Mutations and Having Acquired Resistance to Prior Osimertinib Therapy (INSIGHT 2)
This study was to assess the antitumor activity, safety, tolerability, and pharmacokinetics (PK) of the Mesenchymal-epithelial Transition Factor (MET) inhibitor tepotinib combined with the 3rd generation EGFR inhibitor osimertinib in participants with advanced or metastatic non-small cell lung cancer (NSCLC).
Inclusion Criteria:
Exclusion Criteria:
Fountain Valley, California 92708, United States
New York, New York 10016, United States
New York, New York 10016, United States
Houston, Texas 77030, United States
Gasthuisberg, Belgium
Nord, France
Toulouse, France
Lazio, Italy
Monza, Italy
Varese, Italy
Verona, Italy
Hamamatsu, Japan
Kitaadachi-gun, Japan
Kurume-shi, Japan
Nishinomiya-shi, Japan
Osakasayama-shi, Japan
Ube-shi, Japan
Petaling Jaya, Selangor, Malaysia
Nizniy Novgorod, Russia
Saint Petersburg, Russia
Connexion, Singapore
Hwasun-gun, South Korea
Las Palmas de Gran Canaria, Spain
Bangkoknoi, Thailand
Muang, Thailand
Pathumwan, Thailand